Global Antineoplastic Agents Market Research Report 2023

Antineoplastic Agents Market

New anti-tumor targets and corresponding new anti-tumor agents or means are: targeting cell signal transduction molecules, including protein tyrosine kinase inhibitors, farnesyltransferase (FTase) inhibitors, MAPK signaling pathway inhibitors, and cell cycle regulators.Targeting neovascularization: neovascularization inhibitors;To reduce the detachment, adhesion and basement membrane degradation of cancer cells: anti-metastasis drugs;Targeting telomerase: telomerase inhibitor;Drug resistance to tumor cells: drug resistance reversal agent;Promoting the mature differentiation of malignant cells: differentiation inducers;Specific killing of cancer cells :(antibody or toxin) directed therapy;Enhance the efficacy of radiotherapy and chemotherapy: tumor treatment sensitizers;Enhance or regulate collective immune function: biological response modulator;For oncogenes and tumor suppressor genes: gene therapy - introduction of wild-type tumor suppressor genes, suicide genes, anti-drug resistance genes and antisense oligonucleotides, tumor genetic engineering tumor bacteria.

The global Antineoplastic Agents market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Antineoplastic Agents is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Antineoplastic Agents is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Antineoplastic Agents in Plant Medicine is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Antineoplastic Agents include BMS, MSD, Johnson & Johnson, Pfizer, AstraZeneca, Novartis, Sanofi, Celgene and Roche, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antineoplastic Agents, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antineoplastic Agents.

The Antineoplastic Agents market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Antineoplastic Agents market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antineoplastic Agents companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Antineoplastic Agents Market Report

Core Chapters

1.1 Study Scope

1.2 Market Analysis by Treatment Means

1.2.1 Global Antineoplastic Agents Market Size Growth Rate by Treatment Means: 2018 VS 2022 VS 2029

1.2.2 Chemotherapy

1.2.3 Targeted Therapy

1.2.4 Immunotherapy

1.2.5 Hormonal Therapy (Biologic Therapy)

1.2.6 Others

1.3 Market by Application

1.3.1 Global Antineoplastic Agents Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Plant Medicine

1.3.3 Hormone

1.3.4 Platinum Compounds

1.3.5 Metabolism Of Drug Resistance

1.3.6 Targeting Small Molecules

1.3.7 Drugs For Cancer

1.3.8 Antibiotic

1.3.9 Alkylating Agent

1.3.10 Chemoradiotherapy Protectant

1.3.11 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Antineoplastic Agents Market Perspective (2018-2029)

2.2 Antineoplastic Agents Growth Trends by Region

2.2.1 Global Antineoplastic Agents Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Antineoplastic Agents Historic Market Size by Region (2018-2023)

2.2.3 Antineoplastic Agents Forecasted Market Size by Region (2024-2029)

2.3 Antineoplastic Agents Market Dynamics

2.3.1 Antineoplastic Agents Industry Trends

2.3.2 Antineoplastic Agents Market Drivers

2.3.3 Antineoplastic Agents Market Challenges

2.3.4 Antineoplastic Agents Market Restraints

3.1 Global Top Antineoplastic Agents Players by Revenue

3.1.1 Global Top Antineoplastic Agents Players by Revenue (2018-2023)

3.1.2 Global Antineoplastic Agents Revenue Market Share by Players (2018-2023)

3.2 Global Antineoplastic Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Antineoplastic Agents Revenue

3.4 Global Antineoplastic Agents Market Concentration Ratio

3.4.1 Global Antineoplastic Agents Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antineoplastic Agents Revenue in 2022

3.5 Antineoplastic Agents Key Players Head office and Area Served

3.6 Key Players Antineoplastic Agents Product Solution and Service

3.7 Date of Enter into Antineoplastic Agents Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Antineoplastic Agents Historic Market Size by Type (2018-2023)

4.2 Global Antineoplastic Agents Forecasted Market Size by Type (2024-2029)

5.1 Global Antineoplastic Agents Historic Market Size by Application (2018-2023)

5.2 Global Antineoplastic Agents Forecasted Market Size by Application (2024-2029)

6.1 North America Antineoplastic Agents Market Size (2018-2029)

6.2 North America Antineoplastic Agents Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Antineoplastic Agents Market Size by Country (2018-2023)

6.4 North America Antineoplastic Agents Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Antineoplastic Agents Market Size (2018-2029)

7.2 Europe Antineoplastic Agents Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Antineoplastic Agents Market Size by Country (2018-2023)

7.4 Europe Antineoplastic Agents Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Antineoplastic Agents Market Size (2018-2029)

8.2 Asia-Pacific Antineoplastic Agents Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Antineoplastic Agents Market Size by Region (2018-2023)

8.4 Asia-Pacific Antineoplastic Agents Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Antineoplastic Agents Market Size (2018-2029)

9.2 Latin America Antineoplastic Agents Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Antineoplastic Agents Market Size by Country (2018-2023)

9.4 Latin America Antineoplastic Agents Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Antineoplastic Agents Market Size (2018-2029)

10.2 Middle East & Africa Antineoplastic Agents Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Antineoplastic Agents Market Size by Country (2018-2023)

10.4 Middle East & Africa Antineoplastic Agents Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 BMS

11.1.1 BMS Company Detail

11.1.2 BMS Business Overview

11.1.3 BMS Antineoplastic Agents Introduction

11.1.4 BMS Revenue in Antineoplastic Agents Business (2018-2023)

11.1.5 BMS Recent Development

11.2 MSD

11.2.1 MSD Company Detail

11.2.2 MSD Business Overview

11.2.3 MSD Antineoplastic Agents Introduction

11.2.4 MSD Revenue in Antineoplastic Agents Business (2018-2023)

11.2.5 MSD Recent Development

11.3 Johnson & Johnson

11.3.1 Johnson & Johnson Company Detail

11.3.2 Johnson & Johnson Business Overview

11.3.3 Johnson & Johnson Antineoplastic Agents Introduction

11.3.4 Johnson & Johnson Revenue in Antineoplastic Agents Business (2018-2023)

11.3.5 Johnson & Johnson Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Detail

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Antineoplastic Agents Introduction

11.4.4 Pfizer Revenue in Antineoplastic Agents Business (2018-2023)

11.4.5 Pfizer Recent Development

11.5 AstraZeneca

11.5.1 AstraZeneca Company Detail

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca Antineoplastic Agents Introduction

11.5.4 AstraZeneca Revenue in Antineoplastic Agents Business (2018-2023)

11.5.5 AstraZeneca Recent Development

11.6 Novartis

11.6.1 Novartis Company Detail

11.6.2 Novartis Business Overview

11.6.3 Novartis Antineoplastic Agents Introduction

11.6.4 Novartis Revenue in Antineoplastic Agents Business (2018-2023)

11.6.5 Novartis Recent Development

11.7 Sanofi

11.7.1 Sanofi Company Detail

11.7.2 Sanofi Business Overview

11.7.3 Sanofi Antineoplastic Agents Introduction

11.7.4 Sanofi Revenue in Antineoplastic Agents Business (2018-2023)

11.7.5 Sanofi Recent Development

11.8 Celgene

11.8.1 Celgene Company Detail

11.8.2 Celgene Business Overview

11.8.3 Celgene Antineoplastic Agents Introduction

11.8.4 Celgene Revenue in Antineoplastic Agents Business (2018-2023)

11.8.5 Celgene Recent Development

11.9 Roche

11.9.1 Roche Company Detail

11.9.2 Roche Business Overview

11.9.3 Roche Antineoplastic Agents Introduction

11.9.4 Roche Revenue in Antineoplastic Agents Business (2018-2023)

11.9.5 Roche Recent Development

11.10 Lilly

11.10.1 Lilly Company Detail

11.10.2 Lilly Business Overview

11.10.3 Lilly Antineoplastic Agents Introduction

11.10.4 Lilly Revenue in Antineoplastic Agents Business (2018-2023)

11.10.5 Lilly Recent Development

11.11 Bayer

11.11.1 Bayer Company Detail

11.11.2 Bayer Business Overview

11.11.3 Bayer Antineoplastic Agents Introduction

11.11.4 Bayer Revenue in Antineoplastic Agents Business (2018-2023)

11.11.5 Bayer Recent Development

11.12 Abraxis

11.12.1 Abraxis Company Detail

11.12.2 Abraxis Business Overview

11.12.3 Abraxis Antineoplastic Agents Introduction

11.12.4 Abraxis Revenue in Antineoplastic Agents Business (2018-2023)

11.12.5 Abraxis Recent Development

11.13 Gilead

11.13.1 Gilead Company Detail

11.13.2 Gilead Business Overview

11.13.3 Gilead Antineoplastic Agents Introduction

11.13.4 Gilead Revenue in Antineoplastic Agents Business (2018-2023)

11.13.5 Gilead Recent Development

11.14 Wto-Day Order Pharmaceutical

11.14.1 Wto-Day Order Pharmaceutical Company Detail

11.14.2 Wto-Day Order Pharmaceutical Business Overview

11.14.3 Wto-Day Order Pharmaceutical Antineoplastic Agents Introduction

11.14.4 Wto-Day Order Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.14.5 Wto-Day Order Pharmaceutical Recent Development

11.15 Sinopharm

11.15.1 Sinopharm Company Detail

11.15.2 Sinopharm Business Overview

11.15.3 Sinopharm Antineoplastic Agents Introduction

11.15.4 Sinopharm Revenue in Antineoplastic Agents Business (2018-2023)

11.15.5 Sinopharm Recent Development

11.16 Shandong Lvye Pharmaceutical

11.16.1 Shandong Lvye Pharmaceutical Company Detail

11.16.2 Shandong Lvye Pharmaceutical Business Overview

11.16.3 Shandong Lvye Pharmaceutical Antineoplastic Agents Introduction

11.16.4 Shandong Lvye Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.16.5 Shandong Lvye Pharmaceutical Recent Development

11.17 CTTQ

11.17.1 CTTQ Company Detail

11.17.2 CTTQ Business Overview

11.17.3 CTTQ Antineoplastic Agents Introduction

11.17.4 CTTQ Revenue in Antineoplastic Agents Business (2018-2023)

11.17.5 CTTQ Recent Development

11.18 Jiangsu Hengrui Pharmaceutical

11.18.1 Jiangsu Hengrui Pharmaceutical Company Detail

11.18.2 Jiangsu Hengrui Pharmaceutical Business Overview

11.18.3 Jiangsu Hengrui Pharmaceutical Antineoplastic Agents Introduction

11.18.4 Jiangsu Hengrui Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.18.5 Jiangsu Hengrui Pharmaceutical Recent Development

11.19 Qilu Pharmaceutical

11.19.1 Qilu Pharmaceutical Company Detail

11.19.2 Qilu Pharmaceutical Business Overview

11.19.3 Qilu Pharmaceutical Antineoplastic Agents Introduction

11.19.4 Qilu Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.19.5 Qilu Pharmaceutical Recent Development

11.20 Baekdu Mountain Pharmaceutical

11.20.1 Baekdu Mountain Pharmaceutical Company Detail

11.20.2 Baekdu Mountain Pharmaceutical Business Overview

11.20.3 Baekdu Mountain Pharmaceutical Antineoplastic Agents Introduction

11.20.4 Baekdu Mountain Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.20.5 Baekdu Mountain Pharmaceutical Recent Development

11.21 Baida Pharmaceutical

11.21.1 Baida Pharmaceutical Company Detail

11.21.2 Baida Pharmaceutical Business Overview

11.21.3 Baida Pharmaceutical Antineoplastic Agents Introduction

11.21.4 Baida Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.21.5 Baida Pharmaceutical Recent Development

11.22 Jiangsu Haosen Pharmaceutical Group

11.22.1 Jiangsu Haosen Pharmaceutical Group Company Detail

11.22.2 Jiangsu Haosen Pharmaceutical Group Business Overview

11.22.3 Jiangsu Haosen Pharmaceutical Group Antineoplastic Agents Introduction

11.22.4 Jiangsu Haosen Pharmaceutical Group Revenue in Antineoplastic Agents Business (2018-2023)

11.22.5 Jiangsu Haosen Pharmaceutical Group Recent Development

11.23 Hainan Chang'an International Pharmaceutical

11.23.1 Hainan Chang'an International Pharmaceutical Company Detail

11.23.2 Hainan Chang'an International Pharmaceutical Business Overview

11.23.3 Hainan Chang'an International Pharmaceutical Antineoplastic Agents Introduction

11.23.4 Hainan Chang'an International Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.23.5 Hainan Chang'an International Pharmaceutical Recent Development

11.24 Zhejiang Kanglaite Pharmaceutical

11.24.1 Zhejiang Kanglaite Pharmaceutical Company Detail

11.24.2 Zhejiang Kanglaite Pharmaceutical Business Overview

11.24.3 Zhejiang Kanglaite Pharmaceutical Antineoplastic Agents Introduction

11.24.4 Zhejiang Kanglaite Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.24.5 Zhejiang Kanglaite Pharmaceutical Recent Development

11.25 Shandong New Era Pharmaceutical

11.25.1 Shandong New Era Pharmaceutical Company Detail

11.25.2 Shandong New Era Pharmaceutical Business Overview

11.25.3 Shandong New Era Pharmaceutical Antineoplastic Agents Introduction

11.25.4 Shandong New Era Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.25.5 Shandong New Era Pharmaceutical Recent Development

11.26 Liaoning Novino Pharmaceutical

11.26.1 Liaoning Novino Pharmaceutical Company Detail

11.26.2 Liaoning Novino Pharmaceutical Business Overview

11.26.3 Liaoning Novino Pharmaceutical Antineoplastic Agents Introduction

11.26.4 Liaoning Novino Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.26.5 Liaoning Novino Pharmaceutical Recent Development

11.27 Maanshan Fengyuan Pharmaceutical

11.27.1 Maanshan Fengyuan Pharmaceutical Company Detail

11.27.2 Maanshan Fengyuan Pharmaceutical Business Overview

11.27.3 Maanshan Fengyuan Pharmaceutical Antineoplastic Agents Introduction

11.27.4 Maanshan Fengyuan Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.27.5 Maanshan Fengyuan Pharmaceutical Recent Development

11.28 Meiluo Pharmaceutical

11.28.1 Meiluo Pharmaceutical Company Detail

11.28.2 Meiluo Pharmaceutical Business Overview

11.28.3 Meiluo Pharmaceutical Antineoplastic Agents Introduction

11.28.4 Meiluo Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.28.5 Meiluo Pharmaceutical Recent Development

11.29 Shandong Luoxin Pharmaceutical Group

11.29.1 Shandong Luoxin Pharmaceutical Group Company Detail

11.29.2 Shandong Luoxin Pharmaceutical Group Business Overview

11.29.3 Shandong Luoxin Pharmaceutical Group Antineoplastic Agents Introduction

11.29.4 Shandong Luoxin Pharmaceutical Group Revenue in Antineoplastic Agents Business (2018-2023)

11.29.5 Shandong Luoxin Pharmaceutical Group Recent Development

11.30 Zhejiang Yatai Pharmaceutical

11.30.1 Zhejiang Yatai Pharmaceutical Company Detail

11.30.2 Zhejiang Yatai Pharmaceutical Business Overview

11.30.3 Zhejiang Yatai Pharmaceutical Antineoplastic Agents Introduction

11.30.4 Zhejiang Yatai Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)

11.30.5 Zhejiang Yatai Pharmaceutical Recent Development

11.31 Tesaro (GSK)

11.31.1 Tesaro (GSK) Company Detail

11.31.2 Tesaro (GSK) Business Overview

11.31.3 Tesaro (GSK) Antineoplastic Agents Introduction

11.31.4 Tesaro (GSK) Revenue in Antineoplastic Agents Business (2018-2023)

11.31.5 Tesaro (GSK) Recent Development

11.32 Eisai

11.32.1 Eisai Company Detail

11.32.2 Eisai Business Overview

11.32.3 Eisai Antineoplastic Agents Introduction

11.32.4 Eisai Revenue in Antineoplastic Agents Business (2018-2023)

11.32.5 Eisai Recent Development

11.33 Biogen Idec

11.33.1 Biogen Idec Company Detail

11.33.2 Biogen Idec Business Overview

11.33.3 Biogen Idec Antineoplastic Agents Introduction

11.33.4 Biogen Idec Revenue in Antineoplastic Agents Business (2018-2023)

11.33.5 Biogen Idec Recent Development

11.34 Teva

11.34.1 Teva Company Detail

11.34.2 Teva Business Overview

11.34.3 Teva Antineoplastic Agents Introduction

11.34.4 Teva Revenue in Antineoplastic Agents Business (2018-2023)

11.34.5 Teva Recent Development

11.35 AbbVie

11.35.1 AbbVie Company Detail

11.35.2 AbbVie Business Overview

11.35.3 AbbVie Antineoplastic Agents Introduction

11.35.4 AbbVie Revenue in Antineoplastic Agents Business (2018-2023)

11.35.5 AbbVie Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Antineoplastic Agents Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Chemotherapy

    Table 3. Key Players of Targeted Therapy

    Table 4. Key Players of Immunotherapy

    Table 5. Key Players of Hormonal Therapy (Biologic Therapy)

    Table 6. Key Players of Others

    Table 7. Global Antineoplastic Agents Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Antineoplastic Agents Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 9. Global Antineoplastic Agents Market Size by Region (2018-2023) & (US$ Million)

    Table 10. Global Antineoplastic Agents Market Share by Region (2018-2023)

    Table 11. Global Antineoplastic Agents Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 12. Global Antineoplastic Agents Market Share by Region (2024-2029)

    Table 13. Antineoplastic Agents Market Trends

    Table 14. Antineoplastic Agents Market Drivers

    Table 15. Antineoplastic Agents Market Challenges

    Table 16. Antineoplastic Agents Market Restraints

    Table 17. Global Antineoplastic Agents Revenue by Players (2018-2023) & (US$ Million)

    Table 18. Global Antineoplastic Agents Market Share by Players (2018-2023)

    Table 19. Global Top Antineoplastic Agents Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antineoplastic Agents as of 2022)

    Table 20. Ranking of Global Top Antineoplastic Agents Companies by Revenue (US$ Million) in 2022

    Table 21. Global 5 Largest Players Market Share by Antineoplastic Agents Revenue (CR5 and HHI) & (2018-2023)

    Table 22. Key Players Headquarters and Area Served

    Table 23. Key Players Antineoplastic Agents Product Solution and Service

    Table 24. Date of Enter into Antineoplastic Agents Market

    Table 25. Mergers & Acquisitions, Expansion Plans

    Table 26. Global Antineoplastic Agents Market Size by Type (2018-2023) & (US$ Million)

    Table 27. Global Antineoplastic Agents Revenue Market Share by Type (2018-2023)

    Table 28. Global Antineoplastic Agents Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 29. Global Antineoplastic Agents Revenue Market Share by Type (2024-2029)

    Table 30. Global Antineoplastic Agents Market Size by Application (2018-2023) & (US$ Million)

    Table 31. Global Antineoplastic Agents Revenue Market Share by Application (2018-2023)

    Table 32. Global Antineoplastic Agents Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 33. Global Antineoplastic Agents Revenue Market Share by Application (2024-2029)

    Table 34. North America Antineoplastic Agents Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. North America Antineoplastic Agents Market Size by Country (2018-2023) & (US$ Million)

    Table 36. North America Antineoplastic Agents Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Europe Antineoplastic Agents Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Europe Antineoplastic Agents Market Size by Country (2018-2023) & (US$ Million)

    Table 39. Europe Antineoplastic Agents Market Size by Country (2024-2029) & (US$ Million)

    Table 40. Asia-Pacific Antineoplastic Agents Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Asia-Pacific Antineoplastic Agents Market Size by Region (2018-2023) & (US$ Million)

    Table 42. Asia-Pacific Antineoplastic Agents Market Size by Region (2024-2029) & (US$ Million)

    Table 43. Latin America Antineoplastic Agents Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Latin America Antineoplastic Agents Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Latin America Antineoplastic Agents Market Size by Country (2024-2029) & (US$ Million)

    Table 46. Middle East & Africa Antineoplastic Agents Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 47. Middle East & Africa Antineoplastic Agents Market Size by Country (2018-2023) & (US$ Million)

    Table 48. Middle East & Africa Antineoplastic Agents Market Size by Country (2024-2029) & (US$ Million)

    Table 49. BMS Company Detail

    Table 50. BMS Business Overview

    Table 51. BMS Antineoplastic Agents Product

    Table 52. BMS Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 53. BMS Recent Development

    Table 54. MSD Company Detail

    Table 55. MSD Business Overview

    Table 56. MSD Antineoplastic Agents Product

    Table 57. MSD Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 58. MSD Recent Development

    Table 59. Johnson & Johnson Company Detail

    Table 60. Johnson & Johnson Business Overview

    Table 61. Johnson & Johnson Antineoplastic Agents Product

    Table 62. Johnson & Johnson Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 63. Johnson & Johnson Recent Development

    Table 64. Pfizer Company Detail

    Table 65. Pfizer Business Overview

    Table 66. Pfizer Antineoplastic Agents Product

    Table 67. Pfizer Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 68. Pfizer Recent Development

    Table 69. AstraZeneca Company Detail

    Table 70. AstraZeneca Business Overview

    Table 71. AstraZeneca Antineoplastic Agents Product

    Table 72. AstraZeneca Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 73. AstraZeneca Recent Development

    Table 74. Novartis Company Detail

    Table 75. Novartis Business Overview

    Table 76. Novartis Antineoplastic Agents Product

    Table 77. Novartis Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 78. Novartis Recent Development

    Table 79. Sanofi Company Detail

    Table 80. Sanofi Business Overview

    Table 81. Sanofi Antineoplastic Agents Product

    Table 82. Sanofi Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 83. Sanofi Recent Development

    Table 84. Celgene Company Detail

    Table 85. Celgene Business Overview

    Table 86. Celgene Antineoplastic Agents Product

    Table 87. Celgene Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 88. Celgene Recent Development

    Table 89. Roche Company Detail

    Table 90. Roche Business Overview

    Table 91. Roche Antineoplastic Agents Product

    Table 92. Roche Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 93. Roche Recent Development

    Table 94. Lilly Company Detail

    Table 95. Lilly Business Overview

    Table 96. Lilly Antineoplastic Agents Product

    Table 97. Lilly Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 98. Lilly Recent Development

    Table 99. Bayer Company Detail

    Table 100. Bayer Business Overview

    Table 101. Bayer Antineoplastic Agents Product

    Table 102. Bayer Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 103. Bayer Recent Development

    Table 104. Abraxis Company Detail

    Table 105. Abraxis Business Overview

    Table 106. Abraxis Antineoplastic Agents Product

    Table 107. Abraxis Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 108. Abraxis Recent Development

    Table 109. Gilead Company Detail

    Table 110. Gilead Business Overview

    Table 111. Gilead Antineoplastic Agents Product

    Table 112. Gilead Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 113. Gilead Recent Development

    Table 114. Wto-Day Order Pharmaceutical Company Detail

    Table 115. Wto-Day Order Pharmaceutical Business Overview

    Table 116. Wto-Day Order Pharmaceutical Antineoplastic Agents Product

    Table 117. Wto-Day Order Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 118. Wto-Day Order Pharmaceutical Recent Development

    Table 119. Sinopharm Company Detail

    Table 120. Sinopharm Business Overview

    Table 121. Sinopharm Antineoplastic Agents Product

    Table 122. Sinopharm Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 123. Sinopharm Recent Development

    Table 124. Shandong Lvye Pharmaceutical Company Detail

    Table 125. Shandong Lvye Pharmaceutical Business Overview

    Table 126. Shandong Lvye Pharmaceutical Antineoplastic Agents Product

    Table 127. Shandong Lvye Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 128. Shandong Lvye Pharmaceutical Recent Development

    Table 129. CTTQ Company Detail

    Table 130. CTTQ Business Overview

    Table 131. CTTQ Antineoplastic Agents Product

    Table 132. CTTQ Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 133. CTTQ Recent Development

    Table 134. Jiangsu Hengrui Pharmaceutical Company Detail

    Table 135. Jiangsu Hengrui Pharmaceutical Business Overview

    Table 136. Jiangsu Hengrui Pharmaceutical Antineoplastic Agents Product

    Table 137. Jiangsu Hengrui Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 138. Jiangsu Hengrui Pharmaceutical Recent Development

    Table 139. Qilu Pharmaceutical Company Detail

    Table 140. Qilu Pharmaceutical Business Overview

    Table 141. Qilu Pharmaceutical Antineoplastic Agents Product

    Table 142. Qilu Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 143. Qilu Pharmaceutical Recent Development

    Table 144. Baekdu Mountain Pharmaceutical Company Detail

    Table 145. Baekdu Mountain Pharmaceutical Business Overview

    Table 146. Baekdu Mountain Pharmaceutical Antineoplastic Agents Product

    Table 147. Baekdu Mountain Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 148. Baekdu Mountain Pharmaceutical Recent Development

    Table 149. Baida Pharmaceutical Company Detail

    Table 150. Baida Pharmaceutical Business Overview

    Table 151. Baida Pharmaceutical Antineoplastic Agents Product

    Table 152. Baida Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 153. Baida Pharmaceutical Recent Development

    Table 154. Jiangsu Haosen Pharmaceutical Group Company Detail

    Table 155. Jiangsu Haosen Pharmaceutical Group Business Overview

    Table 156. Jiangsu Haosen Pharmaceutical Group Antineoplastic Agents Product

    Table 157. Jiangsu Haosen Pharmaceutical Group Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 158. Jiangsu Haosen Pharmaceutical Group Recent Development

    Table 159. Hainan Chang'an International Pharmaceutical Company Detail

    Table 160. Hainan Chang'an International Pharmaceutical Business Overview

    Table 161. Hainan Chang'an International Pharmaceutical Antineoplastic Agents Product

    Table 162. Hainan Chang'an International Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 163. Hainan Chang'an International Pharmaceutical Recent Development

    Table 164. Zhejiang Kanglaite Pharmaceutical Company Detail

    Table 165. Zhejiang Kanglaite Pharmaceutical Business Overview

    Table 166. Zhejiang Kanglaite Pharmaceutical Antineoplastic Agents Product

    Table 167. Zhejiang Kanglaite Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 168. Zhejiang Kanglaite Pharmaceutical Recent Development

    Table 169. Shandong New Era Pharmaceutical Company Detail

    Table 170. Shandong New Era Pharmaceutical Business Overview

    Table 171. Shandong New Era Pharmaceutical Antineoplastic Agents Product

    Table 172. Shandong New Era Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 173. Shandong New Era Pharmaceutical Recent Development

    Table 174. Liaoning Novino Pharmaceutical Company Detail

    Table 175. Liaoning Novino Pharmaceutical Business Overview

    Table 176. Liaoning Novino Pharmaceutical Antineoplastic Agents Product

    Table 177. Liaoning Novino Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 178. Liaoning Novino Pharmaceutical Recent Development

    Table 179. Maanshan Fengyuan Pharmaceutical Company Detail

    Table 180. Maanshan Fengyuan Pharmaceutical Business Overview

    Table 181. Maanshan Fengyuan Pharmaceutical Antineoplastic Agents Product

    Table 182. Maanshan Fengyuan Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 183. Maanshan Fengyuan Pharmaceutical Recent Development

    Table 184. Meiluo Pharmaceutical Company Detail

    Table 185. Meiluo Pharmaceutical Business Overview

    Table 186. Meiluo Pharmaceutical Antineoplastic Agents Product

    Table 187. Meiluo Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 188. Meiluo Pharmaceutical Recent Development

    Table 189. Shandong Luoxin Pharmaceutical Group Company Detail

    Table 190. Shandong Luoxin Pharmaceutical Group Business Overview

    Table 191. Shandong Luoxin Pharmaceutical Group Antineoplastic Agents Product

    Table 192. Shandong Luoxin Pharmaceutical Group Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 193. Shandong Luoxin Pharmaceutical Group Recent Development

    Table 194. Zhejiang Yatai Pharmaceutical Company Detail

    Table 195. Zhejiang Yatai Pharmaceutical Business Overview

    Table 196. Zhejiang Yatai Pharmaceutical Antineoplastic Agents Product

    Table 197. Zhejiang Yatai Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 198. Zhejiang Yatai Pharmaceutical Recent Development

    Table 199. Tesaro (GSK) Company Detail

    Table 200. Tesaro (GSK) Business Overview

    Table 201. Tesaro (GSK) Antineoplastic Agents Product

    Table 202. Tesaro (GSK) Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 203. Tesaro (GSK) Recent Development

    Table 204. Eisai Company Detail

    Table 205. Eisai Business Overview

    Table 206. Eisai Antineoplastic Agents Product

    Table 207. Eisai Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 208. Eisai Recent Development

    Table 209. Biogen Idec Company Detail

    Table 210. Biogen Idec Business Overview

    Table 211. Biogen Idec Antineoplastic Agents Product

    Table 212. Biogen Idec Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 213. Biogen Idec Recent Development

    Table 214. Teva Company Detail

    Table 215. Teva Business Overview

    Table 216. Teva Antineoplastic Agents Product

    Table 217. Teva Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 218. Teva Recent Development

    Table 219. AbbVie Company Detail

    Table 220. AbbVie Business Overview

    Table 221. AbbVie Antineoplastic Agents Product

    Table 222. AbbVie Revenue in Antineoplastic Agents Business (2018-2023) & (US$ Million)

    Table 223. AbbVie Recent Development

    Table 224. Research Programs/Design for This Report

    Table 225. Key Data Information from Secondary Sources

    Table 226. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Antineoplastic Agents Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Antineoplastic Agents Market Share by Type: 2022 VS 2029

    Figure 3. Chemotherapy Features

    Figure 4. Targeted Therapy Features

    Figure 5. Immunotherapy Features

    Figure 6. Hormonal Therapy (Biologic Therapy) Features

    Figure 7. Others Features

    Figure 8. Global Antineoplastic Agents Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 9. Global Antineoplastic Agents Market Share by Application: 2022 VS 2029

    Figure 10. Plant Medicine Case Studies

    Figure 11. Hormone Case Studies

    Figure 12. Platinum Compounds Case Studies

    Figure 13. Metabolism Of Drug Resistance Case Studies

    Figure 14. Targeting Small Molecules Case Studies

    Figure 15. Drugs For Cancer Case Studies

    Figure 16. Antibiotic Case Studies

    Figure 17. Alkylating Agent Case Studies

    Figure 18. Chemoradiotherapy Protectant Case Studies

    Figure 19. Other Case Studies

    Figure 20. Antineoplastic Agents Report Years Considered

    Figure 21. Global Antineoplastic Agents Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 22. Global Antineoplastic Agents Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 23. Global Antineoplastic Agents Market Share by Region: 2022 VS 2029

    Figure 24. Global Antineoplastic Agents Market Share by Players in 2022

    Figure 25. Global Top Antineoplastic Agents Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antineoplastic Agents as of 2022)

    Figure 26. The Top 10 and 5 Players Market Share by Antineoplastic Agents Revenue in 2022

    Figure 27. North America Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. North America Antineoplastic Agents Market Share by Country (2018-2029)

    Figure 29. United States Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Canada Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Europe Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Europe Antineoplastic Agents Market Share by Country (2018-2029)

    Figure 33. Germany Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. France Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. U.K. Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Italy Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Russia Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Nordic Countries Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Asia-Pacific Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Asia-Pacific Antineoplastic Agents Market Share by Region (2018-2029)

    Figure 41. China Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Japan Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. South Korea Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Southeast Asia Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. India Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Australia Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Latin America Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 48. Latin America Antineoplastic Agents Market Share by Country (2018-2029)

    Figure 49. Mexico Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 50. Brazil Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 51. Middle East & Africa Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 52. Middle East & Africa Antineoplastic Agents Market Share by Country (2018-2029)

    Figure 53. Turkey Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 54. Saudi Arabia Antineoplastic Agents Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 55. BMS Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 56. MSD Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 57. Johnson & Johnson Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 58. Pfizer Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 59. AstraZeneca Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 60. Novartis Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 61. Sanofi Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 62. Celgene Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 63. Roche Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 64. Lilly Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 65. Bayer Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 66. Abraxis Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 67. Gilead Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 68. Wto-Day Order Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 69. Sinopharm Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 70. Shandong Lvye Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 71. CTTQ Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 72. Jiangsu Hengrui Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 73. Qilu Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 74. Baekdu Mountain Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 75. Baida Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 76. Jiangsu Haosen Pharmaceutical Group Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 77. Hainan Chang'an International Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 78. Zhejiang Kanglaite Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 79. Shandong New Era Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 80. Liaoning Novino Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 81. Maanshan Fengyuan Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 82. Meiluo Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 83. Shandong Luoxin Pharmaceutical Group Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 84. Zhejiang Yatai Pharmaceutical Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 85. Tesaro (GSK) Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 86. Eisai Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 87. Biogen Idec Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 88. Teva Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 89. AbbVie Revenue Growth Rate in Antineoplastic Agents Business (2018-2023)

    Figure 90. Bottom-up and Top-down Approaches for This Report

    Figure 91. Data Triangulation

    Figure 92. Key Executives Interviewed